The results from the BT142 IDH1 mutant tumor model reported herein, which shows similarity with the proneural subset of glioma patients from TCGA, represents an enticing potential opportunity for the application of a brain-penetrant IDH1 mutant inhibitor that may benefit patients clinically. Here, IDH1 is linked to central nervous system cancer.